We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Comprehensive Blood Safety Portfolio Launched at Arab Health 2014

By LabMedica International staff writers
Posted on 04 Feb 2014
Print article
Image: Roche’s Cobas modular analyzer for the "Roche Blood Safety Solution" launched at Arab Health 2014 (Photo courtesy of Roche Diagnostics).
Image: Roche’s Cobas modular analyzer for the "Roche Blood Safety Solution" launched at Arab Health 2014 (Photo courtesy of Roche Diagnostics).
Image: Arab Health delegates meet with Roche delegates at the 2014 Arab Health Exhibition and Congress (Photo courtesy of Roche Diagnostics).
Image: Arab Health delegates meet with Roche delegates at the 2014 Arab Health Exhibition and Congress (Photo courtesy of Roche Diagnostics).
A first in the Middle East, a comprehensive blood-screening portfolio from a single source provides advanced serology screening and nucleic acid testing (NAT) technologies at blood centers, enhancing health standards in the region.

Roche Diagnostics Middle East (RDME), of the Roche company (Basel, Switzerland), has now launched the "Roche Blood Safety Solution" (RBSS) at the 2014 Arab Health Congress (Dubai, UAE), the largest healthcare exhibition and education congress in the Middle East. The RBSS portfolio, the first of its kind in the region, delivers reliability and workflow efficiency for Middle East blood centers, reaffirming RDME’s dedication to providing first class diagnostics in the region.

RBSS now enables patients and communities in the region to benefit from a dedicated, safe and efficient, reliable blood supply. The blood supply is made safe by a reduction in manual steps as well as excellent state-of-the-art assay sensitivity and genotype coverage. With technologies such as electrochemiluminescence (ECL) and polymerase chain reaction (PCR), laboratories benefit from high specificity and NAT real-time-target-discrimination. The systems provide the highest reliability available, excellent traceability and cross-contamination control, and less downtime.

Roche is the first IVD company to have a management center and a logistics hub in the Middle East, enabling RDME to develop from being a regional supplier into becoming a local IVD partner for its customers. The RBSS portfolio safeguards patients through leading technologies with dedication to, and investment in, the safety of the world’s blood supply. “Owing largely to our dedication to safeguard the world’s blood supply through technological innovations and drug development, Roche Diagnostics has become the preferred partner in the Blood Bank Industry,” said Michael Heuer, President of Europe, Middle East, Africa, and Latin America at Roche Diagnostics.

“RBSS benefits from the design, support, and streamlined supply chain that you would associate with [Roche]. We are proud to bring RBSS to the Middle East,” added Moritz Hartmann, General Manager of Roche Diagnostics Middle East. Roche offers service and support for reliability in all its workflow solutions, including the RBSS blood-screening platform, with dependable systems that help blood centers enhance workflow efficiency, minimizing processing time. The RBSS workflow solution is driving the concept of automation and setting new industry standards in diagnostic testing. Molecular testing processes will be brought together in a highly automated solution, without the need for manual transfer steps and with results calculated automatically and sent to the laboratory information system. The ease of operation coupled with ease of training result in staff competent in the use of RBSS systems. Furthermore, support structures in the Middle East help ensure operation of the systems with less downtime.

Related Links:

Roche 
Arab Health Congress


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more